I thought I'd follow up with some charts, cause who does't love a chart?!
Based on current operating expenditure and assuming a scaled increase in cash receipts to that $14.7m number, I anticipate CF+ to be officially reached by around this time next year -- tapping into as little as $2m of their current cash reserves.
FY21 Q4: -$1.2m
FY22 Q1: -$0.5m
FY22 Q2: -$0.2m
These are just approximates. It should be noted any abnormal expenses, churn and changes in forex may cause some variation here.
The one-off quarter of CF+ (as a result of covid cost reductions and payments for government/research incentives) and expenses related to the recent legal settlement, have made for a rather inconsistent looking chart. So on a trailing 12 month basis, there's an overhang of large outgoing cash expenditure. But it's really not the case since they're one offs. Once we're 12 months past that legal settlement expense, the TTM operating cashflow improves dramatically and returns to the improving long-term trend that's been in place since late FY19.
Now, having said all that, if they suddenly decide to make another acquisition, all of this goes out the window. But hopefully in the immediate future that's not on the cards, until they reach CF+ and start adding to their cash reserves through actual revenue.
Operating Cashflow on a Quarterly basis
Operating Cashflow on a Trailing 12-month basis
Net Cashflow on a Trailing 12-month basis (including investment/acquisition costs)
*Ignore the (k) on these charts, it should be in millions. 
(20min delay)